Status:
COMPLETED
An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postme...
Eligibility Criteria
Inclusion
- Postmenopausal woman with early breast cancer who are prescribed with anastrozole as adjuvant endocrine therapy under the routine clinical practice.
- Histologically or cytologically proven to be HR+(ER or PR +)
- No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
- Provision of written informed consent
Exclusion
- Recurrence of breast cancer
- Known hypersensitivity to anastrozole or to any of its excipients
- Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize adherence with the trial protocol: Amenorrhea\<12 months and a intact uterus; Previous inclusion in the present study; Participation in a other clinical study during the last 30 days·
- Women who does not agreed to participate the program
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT00737009
Start Date
August 1 2008
End Date
March 1 2011
Last Update
June 22 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Hanoi, Vietnam
2
Research Site
Ho Chi Minh City, Vietnam
3
Research Site
Huế, Vietnam